A meta-analysis of placebo-controlled trials of omega-3 fatty acid augmentation in schizophrenia: Possible stage-specific effects.
Level 1 - systematic review of randomized trials
Meta-analysis of randomized, double-blind, placebo-controlled trials
What was done
Authors conducted a meta-analysis of published randomized, double-blind, placebo-controlled clinical trials evaluating the efficacy of omega-3 fatty acid supplementation across various clinical stages of schizophrenia.
What was found
Ten studies were included. The abstract provides no numerical data, effect sizes, confidence intervals, or p-values, reporting only qualitative directions: - Prodromal phase: Omega-3 reduced psychotic symptom severity and lowered conversion rates to first-episode psychosis. - First-episode schizophrenia: Omega-3 decreased nonpsychotic symptoms, reduced required antipsychotic dosages, and improved early treatment response rates. - Stable chronic schizophrenia: Omega-3 had mixed results, with significant benefit reported in only a subset of patients. - Chronic schizophrenia with acute exacerbation or antipsychotic discontinuation: Omega-3 supplementation resulted in worsening of psychotic symptoms.
Why it matters
This review highlights possible stage-specific effects of omega-3 supplementation in schizophrenia, suggesting it may be beneficial early in the disease course but potentially detrimental during acute exacerbations in chronic illness.
Limits
The abstract provides no numerical figures, statistical measures of effect, or total participant sample size. The total of 10 studies split across multiple disease stages suggests subgroup analyses may be based on very small study counts. Fatty acid formulations, dosages, and treatment durations were not reported.
Cited by
- supports Supplementation with at least 1 gram of omega-3 containing EPA per day for 8 to 12 weeks showed modest benefit for early-phase psychosis and schizophrenia, but did not have the same effect for chronic schizophrenia.